H7N9 pIIV

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

InfluenzaInfluenza A Virus, H7N9 Subtype

Phase 1

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

CompletedNCT02957656

National Institute of Allergy and Infectious Diseases (NIAID)Influenza A Virus, H7N9 Subtype

Start: 2016-12-31Updated: 2018-10-02

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

CompletedNCT03581903

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2017-09-19End: 2019-02-06Updated: 2019-03-25